Seminal
The magazine and atlas of EU-funded researchA new publication from the web and AI team at Scott Charnley

Atlas / Italy

Marie Skłodowska-Curie Action · Running

ARMOR Next-generation biomimetic vesicles for combating antimicrobial resistance in chronic biofilm infections

Coordinator
Universita Degli Studi Di Roma Tor Vergata, Italy
Runs
1 March 2027 to 28 February 2031
Status
Running
EU funding
€1.6m
Total cost
—
Partners
14 organisations in 11 countries
Type
Marie Skłodowska-Curie Action
Grant agreement
101343634

What the project is doing

In the project's own words, from its summary on CORDIS.

ARMOR addresses a major challenge in modern medicine: chronic biofilm-associated infections, which are highly resistant to antibiotics and closely linked to antimicrobial resistance. The project will develop a new generation of safe, biomimetic nanovesicles inspired by bacterial outer membrane vesicles that can penetrate biofilms and deliver therapeutics directly to the infection site. By combining detoxified bacterial membrane components with synthetic lipids and responsive materials, ARMOR aims to create programmable vesicles that release their cargo only under biofilm-specific conditions such as acidic pH or bacterial enzymes.

The platform will integrate multiple antimicrobial strategies, including antibiotics, antimicrobial peptides, enzymes, and light- and ultrasound-activated agents, to achieve targeted and synergistic biofilm eradication. A distinctive feature of ARMOR is its closed design-build-test-learn framework, in which artificial intelligence, advanced imaging, and quantitative in vitro and in vivo data are combined to iteratively optimise vesicle design, delivery, efficacy, and safety.

The project brings together an international, interdisciplinary, and intersectoral consortium spanning academia and industry across Europe and beyond. Through structured staff secondments, shared training, and joint research activities, ARMOR will promote deep transfer of knowledge and build durable collaboration networks. ARMOR is expected to deliver validated preclinical lead formulations, AI-enabled optimisation workflows, and scalable approaches for vesicle production, stabilisation, and quality control.

In the longer term, the project will strengthen Europe’s capacity to develop precision anti-infective therapies, reduce reliance on conventional antibiotics, and improve the management of chronic biofilm infections and antimicrobial resistance.

Topics

Who is involved

OrganisationCityCountryRole
Universita Degli Studi Di Roma Tor VergataRomaItalyCoordinator
Consejo Nacional De Investigaciones Cientificas Y Tecnicas (conicet)Buenos AiresARAssociatedpartner
Fundacao Para O Desenvolvimento Da Unesp - FundunespSao PauloBrazilAssociatedpartner
Nexus Biosolutions SAPlan Les OuatesSwitzerlandParticipant
Friedrich-Alexander-Universitaet Erlangen-NuernbergErlangenGermanyParticipant
Asociacion Centro De Investigacion Cooperativa En Biomateriales- Cic BiomaguneSan SebastianSpainParticipant
GlobeVAC OyEspooFinlandParticipant
Helsingin YliopistoHelsinkiFinlandParticipant
Maibe SRLRomaItalyParticipant
Universita Degli Studi Di CataniaCataniaItalyParticipant
Lebanese American UniversityBeirutLBAssociatedpartner
Universite Cheikh Anta Diop De DakarDakar FannSNAssociatedpartner
Chulalongkorn UniversityBangkokTHAssociatedpartner
Acibadem Mehmet Ali Aydinlar UniversityIstanbulTürkiyeParticipant

Source: CORDIS, European Commission. Data of 5 Nov 2026, reused under the Commission's reuse policy. View on CORDIS